{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:42:46Z","timestamp":1786207366457,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The management of intraductal papillary mucinous neoplasms (IPMNs) has evolved through successive International Association of Pancreatology guidelines, aiming to refine surgical indications and improve cancer prevention. With broader adoption of surveillance, the oncologic outcomes of patients resected after follow-up\u2014and the effectiveness of current strategies in preventing malignancy\u2014remain unclear. This study examined how evolving management has influenced surgical selection and cancer prevention, particularly by comparing patients resected at diagnosis versus after surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with presumed IPMN across four International Association of Pancreatology guideline periods (pre-2006, 2006\u20132012 [Sendai], 2012\u20132017 [Fukuoka], and 2017\u20132024 [Fukuoka revisions]) were analysed by clinical trajectory: follow-up without surgery, upfront surgery (resection within 12 months of diagnosis), and post-surveillance resection (PR). Endpoints included surgical indications and rates of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and invasive carcinoma (IC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Across guideline periods, patients managed with surveillance increased from 172 before 2006 to 828 in 2006\u20132012, 1,572 in 2012\u20132017, and 1,193 after 2017, while PR increased from 11 to 29, 60, and 204, respectively. Overall, among 3,304 patients, 2,452 (74%) were managed with surveillance, 548 (17%) underwent upfront surgery, and 304 (9%) had PR. In the PR group, resections for a single high-risk stigmata (HRS) increased from 9% to 48%, and those with multiple HRS up to 20% after 2017. At pathology, LGD decreased from 46% to 17%, whereas HGD and IC increased from 18 to 28% and from 36 to 45%, respectively. In the upfront surgery group, LGD decreased from 49% to 26%. Development of HRS during follow-up was associated with a higher risk of HGD\/IC (odds ratio 2.18,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.008).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While evolving IPMN management has reduced rates of LGD and increased detection of HGD, invasive carcinoma remains frequent at resection after surveillance, as surgery is often delayed until HRS emerge. Improved tools are needed to optimize timing and define appropriate oncologic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19898-2","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:27:11Z","timestamp":1781018831000},"page":"8429-8437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer Risk After Initial Surveillance of Intraductal Papillary Mucinous Neoplasms (IPMNs): Are We Missing the Window for Prevention?"],"prefix":"10.1245","volume":"33","author":[{"given":"Antonio","family":"Pea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Dall\u2019Olio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Solinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"De Pastena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Luchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Crin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia A.","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"1","key":"19898_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1136\/gutjnl-2016-313127","volume":"67","author":"ML Kromrey","year":"2018","unstructured":"Kromrey ML, Bulow R, Hubner J, et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut. 2018;67(1):138\u201345.","journal-title":"Gut."},{"issue":"51","key":"19898_CR2","doi-asserted-by":"publisher","first-page":"e5535","DOI":"10.1097\/MD.0000000000005535","volume":"95","author":"YR Chang","year":"2016","unstructured":"Chang YR, Park JK, Jang JY, Kwon W, Yoon JH, Kim SW. Incidental pancreatic cystic neoplasms in an asymptomatic healthy population of 21,745 individuals: Large-scale, single-center cohort study. Medicine (Baltimore). 2016;95(51):e5535.","journal-title":"Medicine (Baltimore)."},{"issue":"1\u20132","key":"19898_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000090023","volume":"6","author":"M Tanaka","year":"2006","unstructured":"Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6(1\u20132):17\u201332.","journal-title":"Pancreatology."},{"issue":"3","key":"19898_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.pan.2012.04.004","volume":"12","author":"M Tanaka","year":"2012","unstructured":"Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183\u201397.","journal-title":"Pancreatology."},{"issue":"5","key":"19898_CR5","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.pan.2017.07.007","volume":"17","author":"M Tanaka","year":"2017","unstructured":"Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738\u201353.","journal-title":"Pancreatology."},{"issue":"2","key":"19898_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pan.2023.12.009","volume":"24","author":"T Ohtsuka","year":"2024","unstructured":"Ohtsuka T, Fernandez-Del Castillo C, Furukawa T, et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology. 2024;24(2):255\u201370.","journal-title":"Pancreatology."},{"issue":"5","key":"19898_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/MPA.0000000000001047","volume":"47","author":"M Tanaka","year":"2018","unstructured":"Tanaka M. Intraductal papillary mucinous neoplasm of the pancreas as the main focus for early detection of pancreatic adenocarcinoma. Pancreas. 2018;47(5):544\u201350.","journal-title":"Pancreas."},{"issue":"1","key":"19898_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/SLA.0000000000001173","volume":"263","author":"V Adsay","year":"2016","unstructured":"Adsay V, Mino-Kenudson M, Furukawa T, et al. Pathologic evaluation and reporting of intraductal papillary mucinous neoplasms of the pancreas and other tumoral intraepithelial neoplasms of pancreatobiliary tract: Recommendations of Verona consensus meeting. Ann Surg. 2016;263(1):162\u201377.","journal-title":"Ann Surg."},{"issue":"12","key":"19898_CR9","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1097\/PAS.0000000000000533","volume":"39","author":"O Basturk","year":"2015","unstructured":"Basturk O, Hong SM, Wood LD, et al. A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol. 2015;39(12):1730\u201341.","journal-title":"Am J Surg Pathol."},{"issue":"3 Suppl 1","key":"19898_CR10","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.surg.2012.05.019","volume":"152","author":"R Salvia","year":"2012","unstructured":"Salvia R, Malleo G, Marchegiani G, et al. Pancreatic resections for cystic neoplasms: from the surgeon\u2019s presumption to the pathologist\u2019s reality. Surgery. 2012;152(3 Suppl 1):S135\u201342.","journal-title":"Surgery."},{"issue":"4","key":"19898_CR11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1053\/j.gastro.2023.06.022","volume":"165","author":"G Marchegiani","year":"2023","unstructured":"Marchegiani G, Pollini T, Burelli A, et al. Surveillance for presumed BD-IPMN of the pancreas: stability, size, and age identify targets for discontinuation. Gastroenterology. 2023;165(4):1016\u201324.","journal-title":"Gastroenterology."},{"issue":"4","key":"19898_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cgh.2015.08.038","volume":"14","author":"M Moris","year":"2016","unstructured":"Moris M, Bridges MD, Pooley RA, et al. Association between advances in high-resolution cross-section imaging technologies and increase in prevalence of pancreatic cysts from 2005 to 2014. Clin Gastroenterol Hepatol. 2016;14(4):585\u201393.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"19898_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/MPA.0000000000001205","volume":"48","author":"C Ricci","year":"2019","unstructured":"Ricci C, Migliori M, Imbrogno A, et al. Prevalence of asymptomatic intraductal papillary mucinous neoplasms in healthy and ill populations detected by ultrasonography: a single-center study of 6353 outpatients. Pancreas. 2019;48(1):113\u201320.","journal-title":"Pancreas."},{"issue":"1","key":"19898_CR14","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1038\/s41467-020-17917-8","volume":"11","author":"M Noe","year":"2020","unstructured":"Noe M, Niknafs N, Fischer CG, et al. Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nat Commun. 2020;11(1):4085.","journal-title":"Nat Commun."},{"issue":"4","key":"19898_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1053\/j.gastro.2019.06.001","volume":"157","author":"CG Fischer","year":"2019","unstructured":"Fischer CG, Beleva Guthrie V, Braxton AM, et al. Intraductal papillary mucinous neoplasms arise from multiple independent clones, each with distinct mutations. Gastroenterology. 2019;157(4):1123\u201337.","journal-title":"Gastroenterology."},{"issue":"6","key":"19898_CR16","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/SLA.0000000000006530","volume":"283","author":"HS Jung","year":"2026","unstructured":"Jung HS, Han Y, Chae YS, Yun WG, Cho YJ, Seo Y, Choi GW, Kim H, Lee KB, Lee DH, Kwon W. Diagnostic performance of surgical indications for branch-duct or mixed-type intraductal papillary mucinous neoplasms of the revised International Association of Pancreatology (IAP) 2023 guidelines. Annals of Surgery. 2026;283(6):1044\u201350.","journal-title":"Annals of Surgery"},{"issue":"6","key":"19898_CR17","doi-asserted-by":"publisher","first-page":"e980","DOI":"10.1097\/SLA.0000000000003703","volume":"274","author":"A Pulvirenti","year":"2021","unstructured":"Pulvirenti A, Margonis GA, Morales-Oyarvide V, et al. Intraductal papillary mucinous neoplasms: have IAP Consensus Guidelines changed our approach? Results from a multi-institutional study. Ann Surg. 2021;274(6):e980\u20137.","journal-title":"Ann Surg."},{"issue":"3","key":"19898_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.pan.2023.01.011","volume":"23","author":"NCM van Huijgevoort","year":"2023","unstructured":"van Huijgevoort NCM, Hoogenboom SAM, Lekkerkerker SJ, et al. Diagnostic accuracy of the AGA, IAP, and European guidelines for detecting advanced neoplasia in intraductal papillary mucinous neoplasm\/neoplasia. Pancreatology. 2023;23(3):251\u20137.","journal-title":"Pancreatology."},{"issue":"1","key":"19898_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.pan.2023.12.002","volume":"24","author":"E Ohno","year":"2024","unstructured":"Ohno E, Balduzzi A, Hijioka S, et al. Association of high-risk stigmata and worrisome features with advanced neoplasia in intraductal papillary mucinous neoplasms (IPMN): a systematic review. Pancreatology. 2024;24(1):48\u201361.","journal-title":"Pancreatology."},{"issue":"6","key":"19898_CR20","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1007\/s00464-022-09752-3","volume":"37","author":"W Dong","year":"2023","unstructured":"Dong W, Zhen D, Xiaoyan W, et al. The effectiveness of endoscopic ultrasonography findings to distinguish benign and malignant intraductal papillary mucinous neoplasm. Surg Endosc. 2023;37(6):4681\u20138.","journal-title":"Surg Endosc."},{"issue":"3","key":"19898_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.pan.2023.02.008","volume":"23","author":"C Correa-Gallego","year":"2023","unstructured":"Correa-Gallego C, Miyasaka Y, Hozaka Y, et al. Surveillance after resection of non-invasive intraductal papillary mucinous neoplasms (IPMN). A systematic review Pancreatology. 2023;23(3):258\u201365.","journal-title":"A systematic review. Pancreatology."},{"issue":"5","key":"19898_CR22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1053\/j.gastro.2017.07.019","volume":"153","author":"I Pergolini","year":"2017","unstructured":"Pergolini I, Sahora K, Ferrone CR, et al. Long-term risk of pancreatic malignancy in patients with branch duct intraductal papillary mucinous neoplasm in a referral center. Gastroenterology. 2017;153(5):1284\u201394.","journal-title":"Gastroenterology."},{"issue":"6","key":"19898_CR23","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.pan.2020.08.003","volume":"20","author":"D Ciprani","year":"2020","unstructured":"Ciprani D, Weniger M, Qadan M, et al. Risk of malignancy in small pancreatic cysts decreases over time. Pancreatology. 2020;20(6):1213\u20137.","journal-title":"Pancreatology."},{"issue":"1","key":"19898_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.gastro.2022.09.028","volume":"164","author":"A Paniccia","year":"2023","unstructured":"Paniccia A, Polanco PM, Boone BA, et al. Prospective, multi-institutional, real-time next-generation sequencing of pancreatic cyst fluid reveals diverse genomic alterations that improve the clinical management of pancreatic cysts. Gastroenterology. 2023;164(1):117\u201333.","journal-title":"Gastroenterology."},{"issue":"2","key":"19898_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/SLA.0000000000002421","volume":"268","author":"MA Al Efishat","year":"2018","unstructured":"Al Efishat MA, Attiyeh MA, Eaton AA, et al. Multi-institutional validation study of pancreatic cyst fluid protein analysis for prediction of high-risk intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2018;268(2):340\u20137.","journal-title":"Ann Surg."},{"issue":"20","key":"19898_CR26","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1158\/1078-0432.CCR-16-0311","volume":"22","author":"T Hata","year":"2016","unstructured":"Hata T, Dal Molin M, Suenaga M, et al. Cyst fluid telomerase activity predicts the histologic grade of cystic neoplasms of the pancreas. Clin Cancer Res. 2016;22(20):5141\u201351.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"19898_CR27","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1245\/s10434-025-18848-8","volume":"33","author":"AD Singhi","year":"2026","unstructured":"Singhi AD, Wald AI, Smith K, et al. PancreaSeq Genomic Classifier (PancreaSeq GC) improves pancreatic cyst classification and detection of advanced neoplasia: a multi-institutional validation study. Ann Surg Oncol. 2026;33(4):2865\u201375.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"19898_CR28","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.ccell.2025.08.001","volume":"43","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lih TM, Lee JW, et al. Multi-omic profiling of intraductal papillary neoplasms of the pancreas reveals distinct patterns and potential markers of progression. Cancer Cell. 2025;43(11):2156\u201370.","journal-title":"Cancer Cell."},{"issue":"11","key":"19898_CR29","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/jnci\/djae166","volume":"116","author":"JR Habib","year":"2024","unstructured":"Habib JR, Rompen IF, Campbell BA, et al. An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. J Natl Cancer Inst. 2024;116(11):1791\u20137.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"19898_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/SLA.0000000000001817","volume":"266","author":"A Pea","year":"2017","unstructured":"Pea A, Yu J, Rezaee N, et al. Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg. 2017;266(1):133\u201341.","journal-title":"Ann Surg."},{"issue":"9","key":"19898_CR31","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1136\/gutjnl-2017-315062","volume":"67","author":"M Felsenstein","year":"2018","unstructured":"Felsenstein M, Noe M, Masica DL, et al. IPMNs with co-occurring invasive cancers: neighbours but not always relatives. Gut. 2018;67(9):1652\u201362.","journal-title":"Gut."},{"issue":"11","key":"19898_CR32","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/jcp-2023-209012","volume":"76","author":"Y Omori","year":"2023","unstructured":"Omori Y, Furukawa T, Scarpa A, Luchini C. Co-occurring IPMN and pancreatic cancer: the same or different? An overview from histology to molecular pathology. J Clin Pathol. 2023;76(11):734\u20139.","journal-title":"J Clin Pathol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19898-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:49:01Z","timestamp":1786204141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19898-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["19898"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19898-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Claudio Luchini\u2014honoraria from Astellas (consulting, steering committee), and from Bayer, Gilead sciences, MSD, and Medica s.r.l. (consulting and speaker bureau).","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}